National Asset Management, Inc. Immuno Gen, Inc. Transaction History

National Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $28,671 - $52,427	-9,102 Reduced 35.05%	16,864 $76,000
Q1 2022 May 02, 2022	SELL	$4.26 - $7.48 $2,577 - $4,525	-605 Reduced 2.28%	25,966 $124,000
Q4 2021 Jan 28, 2022	SELL	$4.75 - $7.5 $8,493 - $13,410	-1,788 Reduced 6.3%	26,571 $198,000
Q2 2021 Aug 10, 2021	BUY	$5.79 - $8.6 $16,976 - $25,215	2,932 Added 11.53%	28,359 $202,000
Q1 2021 May 13, 2021	BUY	$6.5 - $10.53 $18,044 - $29,231	2,776 Added 12.26%	25,427 $197,000
Q4 2020 Feb 04, 2021	SELL	$3.7 - $7.66 $684 - $1,417	-185 Reduced 0.81%	22,651 $147,000
Q3 2020 Nov 09, 2020	BUY	$3.45 - $4.89 $2,404 - $3,408	697 Added 3.15%	22,836 $90,000
Q2 2020 Jul 31, 2020	SELL	$3.32 - $5.34 $45,842 - $73,734	-13,808 Reduced 38.41%	22,139 $102,000
Q1 2020 May 06, 2020	BUY	$2.12 - $6.8 $76,207 - $244,439	35,947 New	35,947 $123,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.